Protara Therapeutics Inc Stock Price, News & Analysis

Protara Therapeutics (Nasdaq: TARA) reported Q2 2025 financial results and provided updates on its clinical pipeline. The company maintains a strong financial position with $145.6 million in cash and investments, expected to fund operations into mid-2027. Key pipeline developments include:

The company plans to present interim analysis from ADVANCED-2 trial of TARA-002 in BCG-Unresponsive NMIBC patients in Q1 2026, expects to initiate patient dosing in the THRIVE-3 registrational trial of IV Choline Chloride in Q3 2025, and will provide an interim update from the STARBORN-1 Phase 2 trial of TARA-002 in pediatric LMs in Q4 2025.

Q2 2025 financial results showed a net loss of $15.0 million ($0.35 per share), with R&D expenses increasing to $10.8 million and G&A expenses rising to $5.8 million.

Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on cancer and rare disease therapies, has granted inducement equity awards to two new employees. The compensation package includes 14,800 stock options at an exercise price of $3.06 per share and 7,400 RSUs.

The stock options will vest over four years with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over three years with one-third vesting annually. These grants were approved under Nasdaq Listing Rule 5635(c)(4) as material inducements for employment.

["New talent acquisition with equity-based compensation alignment", "Structured vesting schedule promotes employee retention"]

Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on cancer and rare disease therapies, has announced inducement grants to two new employees. The company's Compensation Committee approved 29,500 stock options at an exercise price of $2.80 per share and 14,750 restricted stock units (RSUs) as of July 1, 2025.

The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. The RSUs will vest over three years, with one-third vesting annually. Both grants are contingent on continued employment with Protara.

Catalio Capital Management has successfully closed its fourth venture fund, Catalio Nexus Fund IV, raising over $400 million in commitments. The fund, which has already made 16 investments, received significant backing from existing and new global institutional investors, RIAs, foundations, and endowments.

The firm, which manages $2 billion in assets across private equity, private credit, and public equities strategies, focuses on investing in breakthrough biomedical technology companies founded by serial scientist-entrepreneurs. Notable investments from Fund IV include co-leading PinkDx's $40 million Series A round, participating in Imperative Care's $150M Series E financing, and Alentis Therapeutics' $180M Series D round.

Fund IV has also invested in Protara Therapeutics (NASDAQ:TARA) through a PIPE transaction and launched two new companies focused on immunology and inflammation: Rhapsogen and TBD Pharma, co-founded by Catalio Venture Partners from Rockefeller University and Johns Hopkins University respectively.

Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on cancer and rare disease treatments, has been added to the Russell 3000® Index effective June 30, 2025. The company's pipeline includes clinical trials for TARA-002 in non-muscle invasive bladder cancer and lymphatic malformations, as well as an IV Choline Chloride program for patients on parenteral support.

The Russell 3000® Index, which captures the 4,000 largest U.S. stocks by market capitalization, is widely used by investment managers and institutional investors, with approximately $10.6 trillion in assets benchmarked against Russell US Indexes as of June 2024.

Protara Therapeutics (NASDAQ: TARA) has appointed William "Bill" Conkling as Chief Commercial Officer, bringing over 20 years of experience in commercializing cancer and rare disease therapeutics. Conkling previously served as President and CEO of Rafael Holdings and held key positions at Immunomedics and Novartis Pharmaceuticals. At Immunomedics, he led the U.S. commercial launch of Trodelvy for triple negative breast cancer. During his tenure at Novartis, he served as VP, Global Commercial Head for CAR-T, playing a crucial role in commercializing Kymriah, the first FDA-approved CAR-T therapy. Conkling's appointment aims to strengthen Protara's commercial capabilities as it prepares to transition into a commercial-stage organization with its pipeline including a potential best-in-class bladder cancer therapy and two de-risked rare disease programs.

Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on developing cancer and rare disease therapies, has announced its participation in two upcoming investor conferences. The company will participate in a fireside chat at the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference on May 20, 2025, at 12:30 pm ET in New York. Additionally, management will join the TD Cowen 6th Annual Oncology Innovation Summit for a virtual fireside chat on May 27, 2025, at 1:30 pm ET. Both events will be webcast live and temporarily archived on the company's investor relations website.

Protara Therapeutics (NASDAQ: TARA) reported its Q1 2025 financial results and business updates. Key highlights include positive interim results from the ADVANCED-2 trial of TARA-002 in non-muscle invasive bladder cancer (NMIBC), showing a 100% complete response rate in BCG-Unresponsive patients and 76% in BCG-Naïve patients. The company plans to initiate THRIVE-3, a registrational Phase 3 trial for IV Choline Chloride, in Q3 2025. Financially, Protara reported $157.5 million in cash and investments as of March 31, 2025, expected to fund operations into 2027. The company strengthened its leadership with the appointments of Dr. Leonardo Viana Nicacio as CMO and Dr. Shane Williams as VP of HR. Q1 2025 resulted in a net loss of $11.9 million ($0.29 per share), compared to $11.1 million in Q1 2024.

Protara Therapeutics (TARA) announced inducement grants of stock options and restricted stock units (RSUs) to six new employees. The company's new VP and Chief People Officer, Shane Williams, received 41,000 stock options at $4.32 per share and 20,500 RSUs on April 25, 2025. Additionally, five other new employees were granted a total of 59,100 stock options at $3.46 per share and 29,550 RSUs.

The stock options vest over four years (25% after one year, then 1/36th monthly), while RSUs vest over three years (33 1/3% annually). All grants were approved under the company's 2020 Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4).